Robocath Successfully Performs 1st Carotid Stenting in France with R-One™ Robot

Robocath, a company that designs, develops, and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today it’s successful first robotic carotid stenting at Rennes University Hospital. This breakthrough in the neurovascular field was performed on November 16, using Robocath’s R-One robot, operated by Dr. François Eugène and his team.

The procedure is part of a clinical study, which is the first stage of an ambitious research program launched last July by Robocath and Rennes University Hospital, in partnership with Philips France. It aims to enrich the current and future generations of robotic platforms, with the long-term view of improving the treatment of cerebrovascular incidents (CVA, stroke).

Dr. François Eugène, neurointerventionalist at Rennes University Hospital, said: “I am honored to be one of the first operators in the world working in neurovascular robotics. Until now, there were no clinical investigations in Europe in this area, despite all its potential benefits. Every year, 5.5 million people around the world die from a stroke, and one in two stroke victims live with lifelong consequences. The reason for this is a lack of comprehensive health coverage, due to a shortage of qualified operators and hospitals capable of performing this type of procedure. Strokes must be treated quickly but also with extreme precision. Robotics can operate with millimeter accuracy and offer new possibilities in terms of movement, as well as bringing more comfortable working conditions. In time, I am sure that robotic assistance will provide the population with optimal stroke treatment and equality of access to care in France, as well as in other countries facing the same public health issues.”

Lucien Goffart, CEO of Robocath, added: “Strokes are currently the second most common cause of death worldwide. However, there is huge inequality in terms of care provision. The success of treatment is highly dependent on the operator’s level of experience and the proximity of a center capable of treating the condition. Our robotic solution will enable procedures to be more precise and more reliable, which will benefit stroke patients by greatly improving their treatment. Linked with our remote connection module, in the future our technology could treat 100% of patients in the best possible conditions.”

Philippe Bencteux, president and founder of Robocath, concluded: “Robocath’s founding ambition was to ensure the best possible treatment for all stroke patients. For the first time in the company’s history, this procedure has made that ambition a reality. It is a major step forward in our development; opening up some very promising new possibilities for our next robotic generation. I would like to thank Dr. Eugène for his involvement. With his support, as well as that of Philips France, we intend to showcase the huge potential of robotics in the neurovascular field.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy